NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The stock's rise snapped a four-day losing streak.
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...
This was the stock's second consecutive day of losses.
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback